Cinacalcet HCl (Sensipar/ Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cinacalcet HCl (Sensipar/ Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism

Published:2007-07-01 Issue:07 Volume:68 Page:10-17
ISSN:0301-0430
Container-title:Clinical Nephrology
language:en
Short-container-title:CN

Author:

Sterrett J.R.,Strom J.,Stummvoll H.-K.,Bahner U.,Disney A.,Soroka S.D.,Corpier C.,Arruda J.A.,Schwanauer L.E.,Klassen P.S.,Olson K.A.,Block G.A.

Publisher

Dustri-Verlgag Dr. Karl Feistle

Subject

Nephrology,General Medicine

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta‐analysis of randomized studies;Therapeutic Apheresis and Dialysis;2024-03-18

2. Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism;Kidney International Reports;2023-11

3. The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism;Scientific Reports;2021-09-09

4. Calcimimetics and Bundled Reimbursement;American Journal of Kidney Diseases;2019-03

5. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism;Renal Failure;2019-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP